Investigating a new antibody treatment for HIV in infant macaques
Official title: Understanding reservoir effects and curative potential of a CD3/CCR5 bispecific antibody in infant macaques
Funded at University of California at Davis · NIH-11022874 · Data updated 2026-11-12
This study is testing a new treatment for infants with HIV that uses a special antibody to help reduce the virus in their bodies, and it aims to see how well it works when given soon after starting regular HIV medicine.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project start | August 6, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $710,095 |
| NIH project number | 1R01AI184418-01A1 |
| Project ID | NIH-11022874 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are infants with either limited or robust pre-ART viral replication who are at risk of HIV infection.
✕Less likely to help
Patients who are not infants or those without HIV infection may not receive any benefit from this research.
What this research studies
This research focuses on a bispecific antibody that targets both CD3 and CCR5 to potentially deplete HIV reservoirs in infants. The treatment is administered shortly after the initiation of antiretroviral therapy (ART) and aims to understand its effects on viral replication and the immune response. By studying infant macaques, researchers will assess the safety and effectiveness of this approach in reducing HIV reservoirs and achieving remission. The study will categorize infants based on their viral replication levels to tailor the treatment and measure outcomes effectively.
Why it matters
Potential benefit: If successful, this research could lead to a novel treatment strategy that significantly reduces HIV reservoirs in infants, potentially leading to a cure.
How similar studies have gone: Previous studies have shown promising results with similar bispecific antibody approaches in animal models, indicating potential for success in this novel application.
Where this research is happening
-
University of California at Davis
Davis, United States Active
Researchers
- Principal investigator: Hartigan-O'connor, Dennis J. — University of California at Davis
- Study coordinator: Hartigan-O'connor, Dennis J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.